MX2022000934A - Composiciones estables de nanoparticulas lipidicas cargadas de arnm y procesos de fabricacion. - Google Patents

Composiciones estables de nanoparticulas lipidicas cargadas de arnm y procesos de fabricacion.

Info

Publication number
MX2022000934A
MX2022000934A MX2022000934A MX2022000934A MX2022000934A MX 2022000934 A MX2022000934 A MX 2022000934A MX 2022000934 A MX2022000934 A MX 2022000934A MX 2022000934 A MX2022000934 A MX 2022000934A MX 2022000934 A MX2022000934 A MX 2022000934A
Authority
MX
Mexico
Prior art keywords
mrna
processes
lipid nanoparticles
making
loaded lipid
Prior art date
Application number
MX2022000934A
Other languages
English (en)
Inventor
Frank Derosa
Michael Heartlein
Shrirang Karve
Ashish Sarode
Natalia Vargas Montoya
Priyal Patel
Original Assignee
Translate Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translate Bio Inc filed Critical Translate Bio Inc
Publication of MX2022000934A publication Critical patent/MX2022000934A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona composiciones y procesos mejorados para preparar nanopartículas lipídicas cargadas de ARNm (ARNm-LNP); en algunas modalidades, la presente invención proporciona ARNm-LNP con una estabilidad excepcional y es particularmente útil en los casos en los que se desean LNP que comprenden un contenido bajo o nulo de lípidos modificados con PEG.
MX2022000934A 2019-07-23 2020-07-23 Composiciones estables de nanoparticulas lipidicas cargadas de arnm y procesos de fabricacion. MX2022000934A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962877597P 2019-07-23 2019-07-23
PCT/US2020/043223 WO2021016430A1 (en) 2019-07-23 2020-07-23 Stable compositions of mrna-loaded lipid nanoparticles and processes of making

Publications (1)

Publication Number Publication Date
MX2022000934A true MX2022000934A (es) 2022-02-14

Family

ID=72088362

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000934A MX2022000934A (es) 2019-07-23 2020-07-23 Composiciones estables de nanoparticulas lipidicas cargadas de arnm y procesos de fabricacion.

Country Status (11)

Country Link
US (1) US20210046192A1 (es)
EP (1) EP4003311A1 (es)
JP (1) JP2022542562A (es)
KR (1) KR20220038365A (es)
CN (1) CN114401748A (es)
AU (1) AU2020315962A1 (es)
BR (1) BR112022001192A2 (es)
CA (1) CA3146675A1 (es)
IL (2) IL289944A (es)
MX (1) MX2022000934A (es)
WO (1) WO2021016430A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167587A (zh) 2016-11-11 2019-08-23 摩登纳特斯有限公司 流感疫苗
EP3609534A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. BROAD SPECTRUM VACCINE AGAINST THE INFLUENZA VIRUS
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
JP7275111B2 (ja) 2017-08-31 2023-05-17 モデルナティエックス インコーポレイテッド 脂質ナノ粒子の生成方法
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
CN113166783A (zh) 2018-10-09 2021-07-23 不列颠哥伦比亚大学 包含无有机溶剂和去污剂的转染活性囊泡的组合物和***以及与之相关的方法
TW202139976A (zh) * 2020-01-31 2021-11-01 美商現代公司 製備脂質奈米顆粒之方法
EP4149425A1 (en) * 2020-05-15 2023-03-22 Translate Bio, Inc. Lipid nanoparticle formulations for mrna delivery
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines
IL303195A (en) 2020-11-25 2023-07-01 Akagera Medicines Inc Lipid nanoparticles for delivery of nucleic acids and related methods of use
JP2024509743A (ja) * 2021-02-16 2024-03-05 ザ・ジョンズ・ホプキンス・ユニバーシティ ｉｎ ｖｉｔｒｏおよびｉｎ ｖｉｖｏトランスフェクションのための規定サイズのプラスミドＤＮＡ／脂質粒子の調製方法
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
EP4326227A1 (en) * 2021-04-23 2024-02-28 ModernaTX, Inc. Stabilized formulations
EP4326241A1 (en) * 2021-04-23 2024-02-28 ModernaTX, Inc. Isoquinoline-stabilized lipid nanoparticle formulations
KR20240049810A (ko) 2021-09-03 2024-04-17 큐어백 에스이 핵산 전달용 신규 지질 나노입자
KR20230053998A (ko) 2021-10-15 2023-04-24 (주)지노믹트리 mRNA 발현을 위한 유전자 구조체
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
IL312334A (en) 2021-11-05 2024-06-01 Sanofi Sa RNA vaccine for respiratory syncytial virus
CA3239417A1 (en) 2021-11-30 2023-06-08 Yvonne CHAN Human metapneumovirus vaccines
WO2023114307A1 (en) * 2021-12-15 2023-06-22 Modernatx, Inc. Determination of encapsulation efficiency of lipid nanoparticles
WO2023111262A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
CN116549626A (zh) * 2022-01-27 2023-08-08 深圳瑞吉生物科技有限公司 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2023156487A1 (en) 2022-02-15 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating tear film composition to treat corneal defects
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2024028492A1 (en) 2022-08-04 2024-02-08 Sanofi Quantitative assessment of rna encapsulation
WO2024057237A1 (en) * 2022-09-16 2024-03-21 Pfizer Inc. Lipid nanoparticles
DE202023106198U1 (de) 2022-10-28 2024-03-21 CureVac SE Impfstoff auf Nukleinsäurebasis
WO2024094027A1 (zh) * 2022-11-03 2024-05-10 深圳鸿生生物科技有限公司 用于增强核酸递送的组合物
WO2024094881A1 (en) 2022-11-04 2024-05-10 Sanofi Respiratory syncytial virus rna vaccination
WO2024112717A1 (en) * 2022-11-21 2024-05-30 Avstera Therapeutics Corp. Mrna composition for preventing and treating cancer
WO2024133515A1 (en) 2022-12-20 2024-06-27 Sanofi Rhinovirus mrna vaccine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US7799565B2 (en) 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
CN102245590B (zh) 2008-10-09 2014-03-19 泰米拉制药公司 改善的氨基脂质和递送核酸的方法
EP2365962B1 (en) 2008-11-07 2017-07-05 Massachusetts Institute of Technology Aminoalcohol lipidoids and uses thereof
CA2764609C (en) 2009-06-10 2018-10-02 Alnylam Pharmaceuticals, Inc. Improved cationic lipid of formula i
EP4212514A1 (en) 2011-06-08 2023-07-19 Translate Bio, Inc. Cleavable lipids
PE20150041A1 (es) 2011-10-27 2015-01-28 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
EP2830595B1 (en) 2012-03-29 2019-10-16 Translate Bio, Inc. Ionizable cationic lipids
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
KR102470198B1 (ko) 2014-04-25 2022-11-22 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna 의 정제 방법
MA48050A (fr) 2014-05-30 2020-02-12 Translate Bio Inc Lipides biodégradables pour l'administration d'acides nucléiques
HUE060907T2 (hu) 2014-06-25 2023-04-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
CA2953265C (en) 2014-07-02 2023-09-26 Shire Human Genetic Therapies, Inc. Encapsulation of messenger rna
WO2016118724A1 (en) 2015-01-21 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016118725A1 (en) 2015-01-23 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3310764B1 (en) 2015-06-19 2023-04-19 Massachusetts Institute of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
DK3313829T3 (da) 2015-06-29 2024-06-17 Acuitas Therapeutics Inc Lipider og lipide nanopartikelformuleringer til levering af nukleinsyrer
RS63030B1 (sr) 2015-09-17 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
HUE061564T2 (hu) 2015-10-28 2023-07-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske készítmények nukleinsavak bevitelére
US20190022247A1 (en) 2015-12-30 2019-01-24 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP7245651B2 (ja) 2016-03-30 2023-03-24 インテリア セラピューティクス，インコーポレイテッド Ｃｒｉｓｐｒ／ｃａｓ構成成分のための脂質ナノ粒子製剤
EP3842530A1 (en) 2016-06-13 2021-06-30 Translate Bio, Inc. Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
EP3468537A1 (en) * 2016-06-14 2019-04-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018089540A1 (en) * 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CA3043033A1 (en) 2016-11-10 2018-05-17 Translate Bio, Inc. Improved ice-based lipid nanoparticle formulation for delivery of mrna
CA3041345A1 (en) 2016-11-10 2018-05-17 Shrirang KARVE Improved process of preparing mrna-loaded lipid nanoparticles
US11260149B2 (en) * 2017-05-28 2022-03-01 Niloofar Eslahi Hydrogel for cartilage tissue regeneration
WO2019126783A1 (en) * 2017-12-22 2019-06-27 Otonomy, Inc. Triglyceride otic formulations and uses thereof

Also Published As

Publication number Publication date
CN114401748A (zh) 2022-04-26
IL289984A (en) 2022-03-01
IL289944A (en) 2022-04-01
BR112022001192A2 (pt) 2022-03-15
KR20220038365A (ko) 2022-03-28
US20210046192A1 (en) 2021-02-18
EP4003311A1 (en) 2022-06-01
CA3146675A1 (en) 2021-01-28
JP2022542562A (ja) 2022-10-05
AU2020315962A1 (en) 2022-02-03
WO2021016430A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
MX2022000934A (es) Composiciones estables de nanoparticulas lipidicas cargadas de arnm y procesos de fabricacion.
MX2023005697A (es) Composiciones y metodos para la estabilizacion de vacunas de arnm en nanoparticulas lipidicas.
MX2020007148A (es) Formulaciones.
EA202190916A1 (ru) Ионизируемые аминолипиды
MX2023007137A (es) Nanomateriales que comprenden acetales unidos a ésteres.
WO2017060314A3 (en) 3' utr sequences for stabilization of rna
MX2019005287A (es) Lipidos cationicos para suministro de acido nucleico y su preparacion.
WO2019014395A8 (en) GENERATION OF WATER-SOLUBLE CANNABINOID COMPOUNDS IN PLANT CELL SUSPENSION YEAST AND CROPS AND MATERIAL COMPOSITIONS
MX2024000327A (es) Composiciones y metodos para la administracion de arn mensajero.
MX2017012512A (es) Moléculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas.
MX2017004617A (es) Variantes estabilizadas de alfa amilasa y su uso.
MA40627A (fr) Formulations stables de lipides et de liposomes
WO2019002512A3 (en) GLYCOPROTEINS CUSTOMIZED FROM ENGINEERING AND FULLY FUNCTIONAL
BR112021022909A2 (pt) Processo aprimorado de preparação de nanopartículas lipídicas carregadas com mrna
EP4219532A3 (en) Compositions and methods for transient gene therapy with enhanced stability
MY157811A (en) Beta-serum dairy products, neutral lipid-depleted and/or polar lipid-enriched dairy products, and processes for their production
EP4233843A3 (en) Antibody compositions
BR122013008030B8 (pt) método para produzir células eritroides e método para produzir um produto sanguíneo
MX2013012920A (es) Composiciones que comprenden particulas de hidrogel.
MX2022000183A (es) Lipidos cationicos y usos de estos.
MY163288A (en) Sildenafil-free base-containing film preparation and method for producing same
PH12021500009A1 (en) Rna molecules comprising non-canonical base pairs
WO2019147309A3 (en) Rna nanostructures and methods of making and using rna nanostructures
AU2017248848A1 (en) Enhanced gene delivery methods
MX2021014310A (es) Formulaciones de terlipressina.